Maynard Um
-
-
-
-
-
-
-
UroGen settles JELMYTO patent litigation with Teva
-
-
-
-
-
-
-
Jefferies Starts UroGen Pharma (URGN) at Buy
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Lowered to $40 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Upgrades UroGen Pharma (URGN) to Buy
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $47 at Scotiabank
-
-
-
-
-
-
-
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman
-
418,481 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

